Assessment of the left ventricular function in hematopoietic stem cell transplant patients
Main Article Content
Abstract
Recently, the number of patients who have cancers and hematologic malignancies have been more prevalent worldwide. Due to advancements of hematopoietic stem cell transplantation (HSCT) and chemotherapeutic regimens, the number of hematologic cancer survivors have increased. However, they also have suffered from cardiotoxicity and cardiovascular diseases caused by these treatments. By using two - dimensional echocardiography, this study aims to assess left ventricular function of HSCT patients before and after going through conditioning regimens. There is evidence that the left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) decreased at one month after HSCT (p < 0.05) and both of them recovered at three months after HSCT. The decrease of E velocity, E/A ratio and lateral e’ velocity was also observed at one month post HSCT (p < 0.05).
Article Details
Keywords
cardiotoxicity, speckle tracking, 2-D echocardiography, hematopoietic stem cell transplantation
References
1. International Agency for Research on Cancer - World Health Organization. Global Cancer Observatory. https://gco.iarc.fr/today/fact-sheets-cancers. Published December, 2020. Accessed March 1, 2021.
2. Copelan EA. Hematopoietic Stem-Cell Transplantation. New England Journal of Medicine. 2006; 354(17):1813-1826. doi:10.1056/NEJMra052638.
3. Bhatia S, Francisco L, Carter A, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood. Nov 15 2007;110(10):3784-92. doi:10.1182/blood-2007-03-082933.
4. Bhatia S, Robison LL, Francisco L, et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood. Jun 1 2005;105(11):4215-22. doi:10.1182/blood-2005-01-0035.
5. Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Mar 2012;18(3):348-71. doi:10.1016/j.bbmt.2011.12.519.
6. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. Mar 2015;16(3):233-70. doi:10.1093/ehjci/jev014.
7. Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014;15(10):1063-1093. doi:10.1093/ehjci/jeu192.
8. Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). European journal of heart failure. Jan 2017;19(1):9-42. doi:10.1002/ejhf.654.
9. Poreba M, Gac P, Usnarska-Zubkiewicz L, et al. Echocardiographic evaluation of the early cardiotoxic effect of hematopoietic stem cell transplantation in patients with hematologic malignancies. Leukemia & lymphoma. Sep 2016;57(9):2119-25. doi:10.3109/10428194.2015.1122782.
10. Fujimaki K, Maruta A, Yoshida M, et al. Severe cardiac toxicity in hematological stem cell transplantation: predictive value of reduced left ventricular ejection fraction. Bone marrow transplantation. Feb 2001;27(3):307-10. doi:10.1038/sj.bmt.1702783.
11. Tuzovic M, Mead M, Young PA, Schiller G, Yang EH. Cardiac Complications in the Adult Bone Marrow Transplant Patient. Current oncology reports. Mar 2 2019;21(3):28. doi:10.1007/s11912-019-0774-6.
12. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. Jun 1 2003;97(11):2869-2879. doi:10.1002/cncr.11407.
13. Curigliano G LD, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171-190. doi:10.1016/j.annonc.2019.10.023.
14. Hertenstein B, Stefanic M, Schmeiser T, et al. Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. May 1994;12(5):998-1004. doi:10.1200/jco.1994.12.5.998.
15. Pasvolsky O, Morelli O, Rozovski U, et al. Anthracycline-Induced Cardiotoxicity in Acute Myeloid Leukemia Patients Who Undergo Allogeneic Hematopoietic Stem Cell Transplantation. Clinical lymphoma, myeloma & leukemia. Mar 11 2019;doi:10.1016/j.clml.2019.03.007.
16. Paraskevaidis IA, Makavos G, Tsirigotis P, et al. Deformation Analysis of Myocardial Layers Detects Early Cardiac Dysfunction after Chemotherapy in Bone Marrow Transplantation Patients: A Continuous and Additive Cardiotoxicity Process. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography. Nov 2017;30(11):1091-1102. doi:10.1016/j.echo.2017.07.010.
2. Copelan EA. Hematopoietic Stem-Cell Transplantation. New England Journal of Medicine. 2006; 354(17):1813-1826. doi:10.1056/NEJMra052638.
3. Bhatia S, Francisco L, Carter A, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood. Nov 15 2007;110(10):3784-92. doi:10.1182/blood-2007-03-082933.
4. Bhatia S, Robison LL, Francisco L, et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood. Jun 1 2005;105(11):4215-22. doi:10.1182/blood-2005-01-0035.
5. Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Mar 2012;18(3):348-71. doi:10.1016/j.bbmt.2011.12.519.
6. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. Mar 2015;16(3):233-70. doi:10.1093/ehjci/jev014.
7. Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014;15(10):1063-1093. doi:10.1093/ehjci/jeu192.
8. Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). European journal of heart failure. Jan 2017;19(1):9-42. doi:10.1002/ejhf.654.
9. Poreba M, Gac P, Usnarska-Zubkiewicz L, et al. Echocardiographic evaluation of the early cardiotoxic effect of hematopoietic stem cell transplantation in patients with hematologic malignancies. Leukemia & lymphoma. Sep 2016;57(9):2119-25. doi:10.3109/10428194.2015.1122782.
10. Fujimaki K, Maruta A, Yoshida M, et al. Severe cardiac toxicity in hematological stem cell transplantation: predictive value of reduced left ventricular ejection fraction. Bone marrow transplantation. Feb 2001;27(3):307-10. doi:10.1038/sj.bmt.1702783.
11. Tuzovic M, Mead M, Young PA, Schiller G, Yang EH. Cardiac Complications in the Adult Bone Marrow Transplant Patient. Current oncology reports. Mar 2 2019;21(3):28. doi:10.1007/s11912-019-0774-6.
12. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. Jun 1 2003;97(11):2869-2879. doi:10.1002/cncr.11407.
13. Curigliano G LD, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171-190. doi:10.1016/j.annonc.2019.10.023.
14. Hertenstein B, Stefanic M, Schmeiser T, et al. Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. May 1994;12(5):998-1004. doi:10.1200/jco.1994.12.5.998.
15. Pasvolsky O, Morelli O, Rozovski U, et al. Anthracycline-Induced Cardiotoxicity in Acute Myeloid Leukemia Patients Who Undergo Allogeneic Hematopoietic Stem Cell Transplantation. Clinical lymphoma, myeloma & leukemia. Mar 11 2019;doi:10.1016/j.clml.2019.03.007.
16. Paraskevaidis IA, Makavos G, Tsirigotis P, et al. Deformation Analysis of Myocardial Layers Detects Early Cardiac Dysfunction after Chemotherapy in Bone Marrow Transplantation Patients: A Continuous and Additive Cardiotoxicity Process. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography. Nov 2017;30(11):1091-1102. doi:10.1016/j.echo.2017.07.010.